We propose that heightened resistance to chemotherapy, coupled with the survival advantages conferred by improved mitochondrial function, contribute to the poor outcome observed in patients with high Drp1(-/17) tumor expression (Fig. 2). Here, DNM1L is linked to neoplasm.